Based in Shanghai since 2005, Universal Medica has developed a network of quality relationship with many local health partners.

Our Shanghaï team, with dual expertise in marketing and science, is working closely with our partners in the preparation of study reports on issues and specificities of the health industry in China and integrates practical advice and recommendations thanks to its expertise in the pharmaceutical industry and knowledge of the Chinese market.

New Report - December 2011 - “Drug Safety in China”

We are glad to inform you that our new market analysis report “Drug Safety in China” has now been published.

Be aware of the new MoH rules, from July 2011, tightening the ADR reporting and monitoring environment, for your company to be in line with the Chinese SFDA requirements…

Download the brochure

2010 Report - “Clinical trials in China”

Clinical trial industry has been constantly expanding since 2000, and it has become one of the economic drivers of China.
This report provides key information on how to conduct clinical trial in China, including:
•    Chinese market dynamics
•    Regulatory environment and key regulatory changes, procedures
•    Clinical study design and planning,
•    Market drivers and market barriers of conducting clinical trials in China
•    Main actors of the market (including identification sheets of main CROs operating in China now).

It also helps foreign companies to detect opportunities on the market.

Download the brochure

In order to fit your needs, we seek your opinion about the choice of the next reports topics: please fill this form .

Our custom made reports

Do you need specific information?

Universal Medica China offers customized reports to meet your problems.

For more information, please contact us by email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it